Posterior slab cast shows higher healing rate than total contact cast for diabetic foot ulcers in single-center RCT
This single-center, open-label randomized controlled trial enrolled 99 adults with Type 2 diabetes who had a single neuropathic Wagner grade 2 or 3 plantar diabetic foot ulcer. Participants were randomized to receive either a posterior slab cast (PSC) or a total contact cast (TCC) for off-loading, with follow-up for 6 months. The primary outcome was wound healing rate at 6 months, which was significantly higher in the PSC group (72.9%, 35/48) compared to the TCC group (49%, 25/51), with a hazard ratio of 1.3 (95% CI: 1.03-1.73, P=0.024). Secondary outcomes also favored PSC, including a higher healing rate at 3 months (50% vs 25.5%, P=0.011), greater percentage reduction in ulcer surface area at 4 weeks (63.2% vs 55.6%, P=0.040), and significantly better patient satisfaction scores (4.0 vs 2.5 on a Likert scale, P<0.001). Safety and tolerability data, including adverse events and discontinuations, were not reported. Key limitations include the single-center design and open-label nature, which may introduce bias. The study does not report on long-term outcomes beyond 6 months, complications, or cost-effectiveness. While PSC may represent a more acceptable off-loading alternative to TCC in this specific population, these results are preliminary and require confirmation in larger, multi-center trials with blinded assessment.